<DOC>
	<DOC>NCT00056524</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).</brief_summary>
	<brief_title>Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)</brief_title>
	<detailed_description>This is an "open label" study which means there is no placebo group. Each subject enrolled into the study will receive AVP-923.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>18 to 75 years of age, inclusive Clinical diagnosis of PBA (pseudobulbar affect) If female, must not be pregnant or breast feeding Sensitivity to quinidine or any opiate drugs Current or prior history of major psychiatric disturbance Currently participated in a trial within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>MS</keyword>
	<keyword>CNS</keyword>
	<keyword>AD</keyword>
	<keyword>TBI</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>IEED</keyword>
	<keyword>Emotional</keyword>
</DOC>